Skip to main content
SA

Shields Advanced Therapies

Shields Advanced Therapies partners with health systems to improve patient access to breakthrough advanced therapies, including cell and gene therapies. The company specializes in overcoming operational, financial, and clinical barriers associated with complex advanced care delivery. Through established nationwide partnerships, they facilitate the connection of patients with a broad portfolio of approved and pipeline therapies across numerous medical conditions.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Health systems face significant operational, financial, and clinical challenges in providing patients with access to advanced cell and gene therapies. These complexities can delay or prevent patients from receiving potentially life-changing treatments.

Solution

Shields Advanced Therapies partners with health systems to streamline the delivery of advanced therapies, including approved cell and gene products and investigational treatments. The company leverages its extensive healthcare network and decades of experience to overcome the logistical and financial hurdles associated with these complex therapies. By establishing strategic collaborations, Shields facilitates patient connections to a broad spectrum of advanced treatment options across numerous medical conditions. This approach aims to accelerate patient access and improve treatment outcomes.

Target Audience

Primary customers are health systems and hospitals seeking to enhance their capacity to deliver advanced cell and gene therapies to their patient populations.

Features

  • Partnership model focused on health system integration to facilitate advanced therapy delivery.
  • Expertise in navigating operational, financial, and clinical barriers to complex care.
  • Facilitation of patient access to over 45 approved cell and gene therapy products.
  • Support for patient enrollment in investigational therapies, with over 2,500 currently in development.
  • Broad therapeutic coverage across more than 150 distinct medical conditions.
  • Established track record of successful collaborations with over 1,000 hospitals nationwide.
This profile is AI-generated and may contain inaccuracies.